Stem Cell Transplantation

We are joined by Christopher Hourigan at the EHA annual meeting to discuss his presentation on the impact of conditioning intensity of allogenic transplantation for acute myeloid leukaemia with genomic evidence of residual disease. Questions 1. What different conditioning regimens are typically used before allogeneic haematopoietic stem cell transplantation (HSCT)? (0:05) 2. What factors affect […]

The European Society for Blood and Marrow Transplantation (EBMT) was established in 1974 to allow scientists and physicians involved in clinical bone marrow transplantation to share their experiences and collaborate in studies. Recently, the scope of the organisation has broadened to include work in cellular therapy. The 45^th Annual Meeting of the EBMT was held […]

Since the discovery of the Polycomb group (PcG) gene family in Drosophila as repressors of homeotic (HOX) genes, PcG proteins have been implicated in a range of processes from chromosome X inactivation to stem cell plasticity and differentiation. PcG proteins execute their function through transcriptional repression of the promoter region of a target gene. Although […]

Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT). Most of the PTLDs originate from B-cells. Overall, 60–80% of PTLDs are associated with Epstein-Barr virus (EBV); this can vary depending on PTLD type and time of onset after HSCT.^1,2 The majority of the general population is infected by EBV during their […]

Despite substantial advances in cancer diagnosis and treatment, the long-term survival rate for many cancer patients remains dismal.1 More than 90% of cancer-related mortality is ascribed to disease resurgence months or years after adjuvant therapy, either in the form of local recurrence or in the form of metastatic spread, which are typically refractory to existing […]

Autologous haematopoietic stem-cell transplantation (HSCT) is widely employed in haematological malignancies including multiple myeloma (MM),¹ Hodgkin and non-Hodgkin lymphoma (HL and NHL)^2–5 and acute myeloid leukaemia (AML).^6,7 High-dose chemotherapy is an effective treatment strategy in numerous malignant conditions, however, it requires the subsequent use of autologous HSCT in order to restore bone marrow function, mostly […]

As the development of BCR-ABL1 targeting treatments has continued, patients with chronic phase chronic myeloid leukaemia (CML‑CP) were shown to have similar survival rates in all age groups to that of general population in the era of tyrosine kinase inhibitors (TKIs).¹ First, imatinib and subsequently the second-generation TKIs (2GTKIs) (nilotinib and dasatinib) revolutionised the treatment […]

The overwhelming majority of patients diagnosed with chronic phase chronic myeloid leukaemia (CP-CML) can achieve long-term survival with a good quality of life. In a recent review, it has been suggested that CML patients responsive to tyrosine kinase inhibitors (TKIs) might become a chronic disease, such as diabetes or hypertension, requiring maintenance treatment.¹ If we […]

Haematopoietic stem cell transplantation (HSCT) has become the standard of care for many haematological malignancies, selected solid tumours and some non-malignant disorders.¹ However, it can be associated with serious complications, in particular, veno-occlusive disease (VOD). Approximately 14 % of HSCT patients develop VOD, although incidences of up to 60 % have been reported.^2,3 Incidence is […]